Perrigo: regulation fd disclosure

Form 8-K filed Oct 29, 2026 · items 7.01

What the filing says

Net proceeds from the transaction are expected to be used in accordance with Perrigo’s capital allocation priorities. Goldman Sachs is serving as financial advisor and A&O Shearman is serving as legal advisor for Perrigo.

Read the filing on SEC EDGAR →

Perrigo at a glance

Latest quarterQ3 2026

Revenue$988.6M

Revenue Y/Y-5%

Operating margin2.3%

IndustryPharmaceutical Preparations

Perrigo, Q3 2026: revenue $989M (-5% year over year), operating margin 2.3%. The chart follows the revenue to costs, profit and cash.

Perrigo: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Starry Sea Acquisition Nov 6, 2026
Kontoor Brands Nov 6, 2026
Terawulf Nov 6, 2026
Plains GP Holdings LP Nov 6, 2026
Pono Capital Four Nov 6, 2026
HeartSciences Nov 6, 2026
Agility Robotics Nov 6, 2026
Crown PropTech Acquisitions Nov 6, 2026
Rallybio Nov 6, 2026
Fox Nov 6, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.